

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Previously presented)** A cell line which expresses on the cell surface TF, MUC1, and glycoporphin.
2. **(Cancelled)**
3. **(Previously presented)** The cell line of claim 1 which is selected from the group consisting of
 - (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and
 - (c) subclones of (a) or (b).
4. **(Cancelled)**
5. **(Previously presented)** The cell line of claim 1, comprising a vector which comprises a nucleic acid molecule.
6. **(Original)** The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory

molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual hormone, adjuvant, antibody or other molecules or fragments thereof having biological activity or any combination thereof.

7. **(Withdrawn)** A lysate, a molecule, or a mixture of molecules obtained from the cell line of claim 1.
8. **(Cancelled)**
9. **(Withdrawn)** Dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of claim 7.
10. **(Withdrawn)** Dendritic cells co-incubated or fused with the cells of claim 1.
11. **(Previously presented)** A composition comprising
 - (a) a cell line which expresses on the cell surface TF, MUC1, and glycophorin;
 - (b) a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);
 - (c) dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b); or
 - (d) dendritic cells co-incubated or fused with the cells of (a).
12. **(Previously presented)** The composition of claim 11, which is a pharmaceutical or vaccine composition.
- 13-19. **(Cancelled)**

20. **(Currently amended)** A method for the treatment or prevention of cancers and/or tumourous diseases comprising administering a therapeutically or prophylactically effective amount of ~~the effective amount of~~
- (a) a cell line which expresses on the cell surface TF, MUC1, and glycophorin;
 - (b) a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);
 - (c) dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b);
 - (d) dendritic cells co-incubated or fused with the cells of (a); or
 - (e) the pharmaceutical or vaccine composition of claim 12.
21. **(Cancelled)**
22. **(Previously presented)** The method of claim 20, wherein said cancer or tumourous disease is a cancer of the head and neck, lung, mediastinum, gastrointestinal tract, genitourinary system, gynaecological system, breast, endocrine system, skin, childhood, unknown primary site or metastatic cancer, a sarcoma of the soft tissue and bone, a mesothelioma, a melanoma, a neoplasm of the central nervous system, a lymphoma, a leukaemia, a paraneoplastic syndrome, a peritoneal carcinomatosis, a immunosuppression-related malignancy and/or metastatic cancer.